Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q3 2024 · 10-Q
Revenue$52.00K$52.00K+160.0% vs Q3 2023 Net Income-$5.73M-$5.73MN/M vs Q3 2023 EPS Diluted-$2.83-$2.83N/M vs Q3 2023 Operating Income-$4,552,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,215,000N/M Margins · derivedOperating margin-8753.8%+20416.2 pt vs Q3 2023
Net margin-11023.1%+13536.9 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end